Table of contents
January 2004 Vol 3 No 1
In this issue
p1 | doi:10.1038/nrd1300
Editorial: The conductorless orchestra
p3 | doi:10.1038/nrd1299
News and Analysis
News
News review of 2003
p5 | doi:10.1038/nrd1302
News
Patent watch
Balancing competition and patent law
p8 | doi:10.1038/nrd1289
Patent watch
Inherent anticipation of metabolites
p8 | doi:10.1038/nrd1290
Patent watch
Double-patenting challenge
p8 | doi:10.1038/nrd1292
From the analyst's couch
Lysosomal storage diseases market
p9 | doi:10.1038/nrd1286
Fresh from the Pipeline
Oxaliplatin
p11 | doi:10.1038/nrd1287
Research Highlights
Structure-based drug design: Anthrax attacked!
p13 | doi:10.1038/nrd1291
Neuropharmacology: Antibiotic yields anxiolytic
p14 | doi:10.1038/nrd1293
Neurodegenerative diseases: Shifting the cut of APP
p14 | doi:10.1038/nrd1296
Target validation: Of mice and men and rats...
p15 | doi:10.1038/nrd1288
Adverse drug reactions: A broader perspective
p16 | doi:10.1038/nrd1294
In brief
ADME | Anticancer Drugs | Liver Disease | Screening
p16 | doi:10.1038/nrd1295
Reviews
The IKK NF-
B system: a treasure trove for drug development
Michael Karin, Yumi Yamamoto & Q. May Wang
p17 | doi:10.1038/nrd1279
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model
Anthony W. Norman, Mathew T. Mizwicki & Derek P. G. Norman
p27 | doi:10.1038/nrd1283
Crystal structures of drugs: advances in determination, prediction and engineering
Sharmistha Datta & David J. W. Grant
p42 | doi:10.1038/nrd1280
Fluorescent probes for proteolysis: Tools for drug discovery
Jacques Neefjes & Nico P. Dantuma
p58 | doi:10.1038/nrd1282
Embryonic stem cells in drug discovery
John McNeish
p70 | doi:10.1038/nrd1281
Perspectives
Opinion
Therapeutic vaccination for chronic diseases: a new class of drugs in sight
Martin F. Bachmann & Mark R. Dyer
p81 | doi:10.1038/nrd1284
Opinion
Challenges of implementing pharmacogenetics in the critical care environment
Bradley D. Freeman & Howard L. McLeod
p88 | doi:10.1038/nrd1285
Careers and Recruitment
Correspondence
Correspondence: Substrate reduction therapy in lysosomal storage diseases: a clarification
Fran Platt, Terry Butters & Raymond Dwek
| doi:10.1038/nrd1286-c1
Correspondence: Lysosomal storage diseases market.
Olivier Morand & Hélène Peyro-Saint-Paul
| doi:10.1038/nrd1286-c2
